Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Omics-based tools were coupled with bioinformatics for a systeomics analysis of two biopharma cell types: Chinese hamster ovary (M-CHO and CHO-K1) and SP2/0. Exponential and stationary phase samples revealed more than 10,000 transcripts and 6000 proteins across these two manufacturing cell lines. A statistical comparison of transcriptomics and proteomics data identified downregulated genes involved in protein folding, protein synthesis and protein metabolism, including PPIA-cyclophilin A, HSPD1, and EIF3K, in M-CHO compared to SP2/0 while cell cycle and actin cytoskeleton genes were reduced in SP2/0. KEGG pathway comparisons revealed glycerolipids, glycosphingolipids, ABC transporters, calcium signaling, cell adhesion, and secretion pathways depleted in M-CHO while retinol metabolism was upregulated. KEGG and IPA also indicated apoptosis, RNA degradation, and proteosomes enriched in CHO stationary phase. Alternatively, gene ontology analysis revealed an underrepresentation in ion and potassium channel activities, membrane proteins, and secretory granules including Stxbpt2, Syt1, Syt9, and Cma1 proteins in M-CHO. Additional enrichment strategies involving ultracentrifugation, biotinylation, and hydrazide chemistry identified over 4000 potential CHO membrane and secretory proteins, yet many secretory and membrane proteins were still depleted. This systeomics pipeline has revealed bottlenecks and potential opportunities for cell line engineering in CHO and SP2/0 to improve their production capabilities.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8885639 | PMC |
| http://dx.doi.org/10.1038/s41598-022-06886-1 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Characterization for the Similarity Assessment Between the Proposed Biosimilar SB17 and Ustekinumab Reference Product Using State-of-the-Art Analytical Methods.
Drugs R D
March 2025
Quality Evaluation Team, Samsung Bioepis Co., Ltd, Incheon, South Korea.
Background: SB17 is being developed as a biosimilar to ustekinumab reference product (RP), a human monoclonal antibody (IgG1 kappa immunoglobulin) that binds to the common p40 subunit of cytokines interleukin (IL)-23 and IL-12. Binding to this subunit prevents interaction with their receptor, resulting in modulation in the immune system responses that play a key role in inflammatory disease.
Objective: The objective of this study was to demonstrate structural, physicochemical, and biological similarity between ustekinumab RP and SB17 using various state-of-the-art analytical methods.
Engineering protein glycosylation in CHO cells to be highly similar to murine host cells.
Front Bioeng Biotechnol
February 2023
Michael Smith Laboratories, and Department of Chemical and Biological Engineering, University of British Columbia, Vancouver, BC, Canada.
Since 2015 more than 34 biosimilars have been approved by the FDA. This new era of biosimilar competition has stimulated renewed technology development focused on therapeutic protein or biologic manufacturing. One challenge in biosimilar development is the genetic differences in the host cell lines used to manufacture the biologics.
View Article and Find Full Text PDFRecent developments in miRNA based recombinant protein expression in CHO.
Biotechnol Lett
June 2022
Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran.
Article Synopsis
- - The increasing demand for recombinant therapeutic proteins is driving growth in the biopharmaceutical industry, particularly through enhanced production in mammalian cell lines like Chinese hamster ovary cells.
- - Research has focused on improving host cell productivity using genetic manipulation techniques, including the use of MicroRNAs and various genetic engineering tools like TALEN, ZFN, and CRISPR/Cas.
- - This study reviews methods for selecting target miRNAs in cell line engineering, evaluates gain- or loss-of-function strategies, and discusses the pros and cons of this technology based on laboratory and pilot studies.
Comparative systeomics to elucidate physiological differences between CHO and SP2/0 cell lines.
Sci Rep
February 2022
Allogene Therapeutics, South San Francisco, CA, USA.
Omics-based tools were coupled with bioinformatics for a systeomics analysis of two biopharma cell types: Chinese hamster ovary (M-CHO and CHO-K1) and SP2/0. Exponential and stationary phase samples revealed more than 10,000 transcripts and 6000 proteins across these two manufacturing cell lines. A statistical comparison of transcriptomics and proteomics data identified downregulated genes involved in protein folding, protein synthesis and protein metabolism, including PPIA-cyclophilin A, HSPD1, and EIF3K, in M-CHO compared to SP2/0 while cell cycle and actin cytoskeleton genes were reduced in SP2/0.
View Article and Find Full Text PDFA hybridoma-derived monoclonal antibody with high homology to the aberrant myeloma light chain.
PLoS One
November 2021
BioInterfaces Institute, University of Michigan, Ann Arbor, Michigan, United States of America.
The identification of antibody variable regions in the heavy (VH) and light (VL) chains from hybridomas is necessary for the production of recombinant, sequence-defined monoclonal antibodies (mAbs) and antibody derivatives. This process has received renewed attention in light of recent reports of hybridomas having unintended specificities due to the production of non-antigen specific heavy and/or light chains for the intended antigen. Here we report a surprising finding and potential pitfall in variable domain sequencing of an anti-human CD63 hybridoma.
View Article and Find Full Text PDF